Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Real-world Evaluation of BEOVU (Brolucizumab) Effectiveness and Durability for Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD)

NCT06184360 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT06184360
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06184360 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Real-world Evaluation of BEOVU (Brolucizumab) Effectiveness and Durability for Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD)
Lead sponsor
Novartis Pharmaceuticals
Phase
Observational
Overall status
Completed
Start date
May 31, 2022
Completion date
December 16, 2022
Enrollment
2,079 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular (wet) age-related macular degeneration